Avantor, Inc. Restricted Stock or Unit Expense
Avantor, Inc. (AVTR) reported Restricted Stock or Unit Expense of $2.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestrictedStockExpense · last filed 2026-02-11
- Avantor, Inc. restricted stock or unit expense for the quarter ending 2025-06-30 was $3.70M, a 37.04% increase year-over-year.
- Avantor, Inc. restricted stock or unit expense for the quarter ending 2025-03-31 was $3.30M, a 57.14% increase year-over-year.
- Avantor, Inc. restricted stock or unit expense for the quarter ending 2024-12-31 was $2.70M.
- Avantor, Inc. restricted stock or unit expense for the quarter ending 2024-09-30 was $1.80M, a 5.88% increase year-over-year.
- Avantor, Inc. restricted stock or unit expense for fiscal 2025 was $2.80M, a 69.89% decline from fiscal 2024.
- Avantor, Inc. restricted stock or unit expense for fiscal 2024 was $9.30M, a 200.00% increase from fiscal 2023.
- Avantor, Inc. restricted stock or unit expense for fiscal 2023 was $3.10M, a 57.53% decline from fiscal 2022.
- Avantor, Inc. restricted stock or unit expense for fiscal 2022 was $7.30M, a 1.35% decline from fiscal 2021.
| Period end | Restricted Stock or Unit Expense 3 month | Restricted Stock or Unit Expense 6 month | Restricted Stock or Unit Expense 9 month | Restricted Stock or Unit Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.80M 10-K · filed 2026-02-11 | |||
| 2025-06-30 | $3.70M 10-Q · filed 2025-08-01 | $7.00M 10-Q · filed 2025-08-01 | $9.70M derived: sum of 3 quarters · filed 2026-02-11 | $11.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | $3.30M 10-Q · filed 2025-04-25 | $6.00M derived: sum of 2 quarters · filed 2026-02-11 | $7.80M derived: sum of 3 quarters · filed 2026-02-11 | $10.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $4.50M derived: sum of 2 quarters · filed 2026-02-11 | $7.20M derived: sum of 3 quarters · filed 2026-02-11 | $9.30M 10-K · filed 2026-02-11 |
| 2024-09-30 | $1.80M 10-Q · filed 2024-10-25 | $4.50M derived: sum of 2 quarters · filed 2025-08-01 | $6.60M 10-Q · filed 2024-10-25 | $6.20M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $2.70M 10-Q · filed 2025-08-01 | $4.80M 10-Q · filed 2025-08-01 | $4.40M derived: sum of 3 quarters · filed 2026-02-11 | $6.10M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $2.10M 10-Q · filed 2025-04-25 | $1.70M derived: sum of 2 quarters · filed 2026-02-11 | $3.40M derived: sum of 3 quarters · filed 2026-02-11 | $3.90M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.30M derived: sum of 2 quarters · filed 2026-02-11 | $1.80M derived: sum of 3 quarters · filed 2026-02-11 | $3.10M 10-K · filed 2026-02-11 |
| 2023-09-30 | $1.70M 10-Q · filed 2024-10-25 | $2.20M derived: sum of 2 quarters · filed 2024-10-25 | $3.50M 10-Q · filed 2024-10-25 | $3.90M derived: sum of 4 quarters · filed 2025-02-07 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-07-26 | $1.80M 10-Q · filed 2023-07-28 | $2.20M derived: sum of 3 quarters · filed 2025-02-07 | $5.10M derived: sum of 4 quarters · filed 2025-02-07 |
| 2023-03-31 | $2.30M 10-Q · filed 2024-04-26 | $1.70M derived: sum of 2 quarters · filed 2025-02-07 | $4.60M derived: sum of 3 quarters · filed 2025-02-07 | $7.30M derived: sum of 4 quarters · filed 2025-02-07 |
| 2022-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-07 | $2.30M derived: sum of 2 quarters · filed 2025-02-07 | $5.00M derived: sum of 3 quarters · filed 2025-02-07 | $7.30M 10-K · filed 2025-02-07 |
| 2022-09-30 | $2.90M 10-Q · filed 2023-10-27 | $5.60M derived: sum of 2 quarters · filed 2023-10-27 | $7.90M 10-Q · filed 2023-10-27 | $10.90M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $2.70M 10-Q · filed 2023-07-28 | $5.00M 10-Q · filed 2023-07-28 | $8.00M derived: sum of 3 quarters · filed 2024-02-14 | $9.60M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $2.30M 10-Q · filed 2023-04-28 | $5.30M derived: sum of 2 quarters · filed 2024-02-14 | $6.90M derived: sum of 3 quarters · filed 2024-02-14 | $8.40M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $4.60M derived: sum of 2 quarters · filed 2024-02-14 | $6.10M derived: sum of 3 quarters · filed 2024-02-14 | $7.40M 10-K · filed 2024-02-14 |
| 2021-09-30 | $1.60M 10-Q · filed 2022-10-28 | $3.10M derived: sum of 2 quarters · filed 2022-10-28 | $4.40M 10-Q · filed 2022-10-28 | |
| 2021-06-30 | $1.50M 10-Q · filed 2022-07-29 | $2.80M 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | $1.30M 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | $5.10M 10-K · filed 2023-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |